Search results for "dense bodies"

showing 2 items of 2 documents

Production Strategies for Pentamer-Positive Subviral Dense Bodies as a Safe Human Cytomegalovirus Vaccine

2019

Infections with the human cytomegalovirus (HCMV) are associated with severe clinical manifestations in children following prenatal transmission and after viral reactivation in immunosuppressed individuals. The development of an HCMV vaccine has long been requested but there is still no licensed product available. Subviral dense bodies (DB) are immunogenic in pre-clinical models and are thus a promising HCMV vaccine candidate. Recently, we established a virus based on the laboratory strain Towne that synthesizes large numbers of DB containing the pentameric protein complex gH/gL/UL128-131 (Towne-UL130repΔGFP). The work presented here focuses on providing strategies for the production of a sa…

0301 basic medicineHuman cytomegalovirus030106 microbiologyImmunologyCongenital cytomegalovirus infectiondense bodieslcsh:MedicineBiologyArticleVirus03 medical and health sciencesLetermovirIn vivovaccineDrug DiscoverymedicinePharmacology (medical)cytomegalovirusPharmacologyTransmission (medicine)lcsh:Rmedicine.diseaseVirologycongenital infectionOpen reading frame030104 developmental biologyInfectious DiseasesFKBPsafety vectorgH/gL/UL128-131pentamer complexmedicine.drugVaccines
researchProduct

Therapeutic Vaccination of Hematopoietic Cell Transplantation Recipients Improves Protective CD8 T-Cell Immunotherapy of Cytomegalovirus Infection

2021

Reactivation of latent cytomegalovirus (CMV) endangers the therapeutic success of hematopoietic cell transplantation (HCT) in tumor patients due to cytopathogenic virus spread that leads to organ manifestations of CMV disease, to interstitial pneumonia in particular. In cases of virus variants that are refractory to standard antiviral pharmacotherapy, immunotherapy by adoptive cell transfer (ACT) of virus-specific CD8+ T cells is the last resort to bridge the “protection gap” between hematoablative conditioning for HCT and endogenous reconstitution of antiviral immunity. We have used the well-established mouse model of CD8+ T-cell immunotherapy by ACT in a setting of experimental HCT and mu…

Adoptive cell transfermedicine.medical_treatmentImmunologyCytomegalovirusCD8-Positive T-LymphocytesLymphocyte ActivationCD8+ T cellsVirusCytomegalovirus VaccinesImmunocompromised HostAntigenvaccineMHC class ImedicineImmunology and AllergyCytotoxic T cellAnimalsCells Culturedadoptive cell transferCell ProliferationOriginal ResearchHCMV dense bodiesbiologybusiness.industryVaccinationHematopoietic Stem Cell TransplantationImmunotherapyRC581-607VirologyAdoptive TransferTransplantationMice Inbred C57BLantiviral protectionT cell primingDisease Models AnimalT cell receptor transgenic cellsCytomegalovirus InfectionsHost-Pathogen Interactionsbiology.proteinFemaleVirus Activationsubviral particlesImmunologic diseases. AllergybusinessCD8Frontiers in Immunology
researchProduct